Related Experiment Video
Updated: Jul 15, 2026
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
[Our experiences in treating patients with Hodgkin disease in the last decade]
Zsófia Simon1, Katalin Keresztes, Zsófia Miltényi
1Debreceni Egyetem Orvos- és Egészségtudományi Centrum, Belgyógyászati Intézet, III. Belgyógyászati Klinika, Debrecen. zsocogo@gmail.com
Insights
Treatment for Hodgkin's disease has improved. Early-stage patients benefit from reduced toxicity, while advanced-stage patients require aggressive treatment for better outcomes.
Area of Science:
- Oncology
- Hematology
- Internal Medicine
Context:
- Hodgkin's disease treatment has seen recent advancements.
- This study reviews clinical and histological data from 1995-2004.
- Follow-up averaged 69 months.
Purpose:
- To summarize treatment outcomes for Hodgkin's disease patients.
- To analyze clinical and histological data for treatment optimization.
Summary:
- 163 patients diagnosed with Hodgkin's disease, mean age 36.
- Mixed-cell subtype was most frequent (48.5%).
- Treatment modalities included radiotherapy, chemotherapy, and combined approaches.
- 10-year survival rates: 83% overall, with variations based on stage and prognosis.
- Relapse occurred in 27 patients, with 15 undergoing stem cell transplantation.
- Mortality linked to lymphoma progression, treatment, or secondary malignancies.
Impact:
- Treatment results for Hodgkin's disease have improved.
- Recommendations for tailored treatment strategies based on disease stage and prognosis.
- Suggests reducing treatment toxicity for early-stage favorable disease.
- Advocates for aggressive primary treatment for advanced, unfavorable prognosis cases, accepting potential side effects.
Introduction:
Recently, in the diagnostics and treatment of Hodgkin's disease significant developments have occurred.
Aim:
To summarize the clinical and histological data of patients with Hodgkin's disease, treated at the 3rd Department of Internal Medicine, University of Debrecen between 1995-2004. In 2006 January, the mean follow-up was 69 (12-132) months.
Methods:
Patients data was analyzed by using SPSS statistical software.
Results:
The mean age of the 163 patients at the diagnosis was 36 years (14-75), with bimodal age distribution, the most frequent disease subtype was mixed-cell Hodgkin's disease (48.5%). 41.1% of the patients was at early stage, 15.7% had the worst prognosis, while 28.8% had bulky tumor. 7 patients had radiotherapy, 63 had chemotherapy, while at 92 patients combined modality treatment was used. 61.6% of radiotherapies were involved field, 61 patients received cyclophosphamide, vincristine, procarbazine, prednisolone, adriamycine, bleomycin, vinblastine, 87 adriamycine, bleomycin, vinblastine, 7 had other chemotherapies. As the response to the primary treatment 146 complete, 10 partial remission occurred, while 6 patients showed no response. 10 patients with partial remission and 5 non-responders were continually treated. 27 patients with complete remission had relapse, while 15 had high dose treatment with autologous peripheral stem cell transplantation. During the follow-up 18 patients died, 11 due to the lymphoma progression, or as the result of treatment, 6 had secondary malignancies, 1 due to other reasons. The 10-year prognosed overall survival was 83% (in details: early, advanced, favourable vs. unfavourable: 100% vs. 87.8%, 88.9% vs. 41.6%), the event free survival was 70% (82.6% vs. 70.8%, 64.5% vs. 0%).
Conclusion:
The treatment results of our Hodgkin's disease patients improved, additionally we showed that patients with early stage favourable disease the treatment toxicity should be reduced, while patients with advanced, unfavourable prognosis (10% of all patients) aggressive primary treatment should be used even with more severe side effects and complications.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:28Graves' Disease I: Introduction